bluuebunny/crossref_metadata_2025_split huggingface dataset:
1367-P: Effect of Nationwide Reimbursement of Sensor-Augmented Pump (SAP) Therapy in a Paediatric Type 1 Diabetes (T1D) Population on HbA1c, Hypoglycaemia, and Quality of Life (QoL) According to Age Groups in the RESCUE-Paediatrics Study
Authors: DE RIDDER FRANCESCA , JACOBS SEPPE , CHARLEER SARA , GILLARD PIETER , CASTEELS KRISTINA , VAN AKEN SARA , GIES INGE , MASSA GUY , LYSY PHILIPPE A. , LOGGHE KARL , LEBRETHON MARIE-CHRISTINE , DEPOORTER SYLVIA , LEDEGANCK KRISTIEN J. , DE BLOCK CHRISTOPHE , BRINKER MARIEKE DEN ,   ON BEHALF OF THE RESCUE TRIALISTS
Published: June 2019

Background: Long-term real-life data of SAP in pediatric T1D patients are scarce.
Objectives: To assess the impact of 12 months use of SAP in a nationwide study of pediatric T1D patients on HbA1c, hypoglycemia and quality of life1 according to age.
Methods: Between 12/2014 and 02/2017, 75 children entered Belgian reimbursement system for SAP and were followed for 12 months. Study endpoints included change in HbA1c at 0-4-8-12 months; time-in-hypoglycemia (&lt;70mg/dl) and time-in-severe-hypoglycemia (&lt;50mg/dl) (%/day) at 0-12 months; and QoL2 at 0-12 months. Puberty was defined as age ≥11.6y in boys and ≥11.2y in girls.
Results: Seventy-three patients used SAP for 12 months. Baseline HbA1c (7.2±0.7%) decreased to 7.1±0.8% at 4 months (p=0.02), remained stable at 8 months (p=0.03) and 12 months (p=0.15). In pubertal children (n=29) baseline was 7.1±0.7%. It decreased to 6.8±0.7% at 4 months (p=0.003), increased to 7.0±0.8% at 8 months (p=0.02) and to 7.1±0.8% at 12 months (p=0.20). In prepubertal children (n=43) baseline Hb1Ac was 7.3±0.7%; and evolved towards 7.1±0.8% at 12 months (p=0.40).
In pubertal children, time-in-hypoglycemia decreased from 7.1±6.9% to 5.7±5.1% (p=0.06) the first year, while time-in-severe-hypoglycemia did not significantly change (1.0±1.7% to 1.3±2.0%). In prepubertal children, both parameters did not significantly change (5,9±5,4% to 5,6±3,4% - 0,8±1,4% to 1,1±1,4%).
In pubertal children and their parents, QoL did not significantly change. In prepubertal children, satisfaction scores improved after 12months from 67±12 to 70±9 (p=0.026).
Conclusions: One year reimbursement of SAP in pediatric T1D patients improved HbA1c in the first 8 months in all; tended to decrease hypoglycemia in pubertal children; while improving QoL in prepubertal children.
1RESCUE-NCT02601729. 2Impact, satisfaction, worry (children) and parents.

Disclosure
F. De Ridder: None. S. Jacobs: None. S. Charleer: Other Relationship; Self; Roche Diabetes Care. P. Gillard: None. K. Casteels: None. S. Van Aken: None. I. Gies: None. G. Massa: None. P.A. Lysy: None. K. Logghe: None. M. Lebrethon: None. S. Depoorter: None. K.J. Ledeganck: None. C. De Block: None. M. den Brinker: None.
1370-P: Pediatric to Adult Transition Interventions and Outcomes in Type 1 Diabetes: A Scoping Review
Authors: LUNDGRIN ERIKA L. , BLANCHETTE JULIA E. , MUCCI ANDREA 
Published: June 2019

Introduction: Adolescents and young adults (AYA) transitioning from pediatric to adult T1D care struggle with glycemic control and continuity of care while experiencing psychosocial complexities. The purpose of this review was to examine associations between transition interventions and relevant outcomes.
Methods: A predefined search strategy was used to retrieve papers published in the past five years evaluating transition programs for AYA with T1D. Nine observational studies and eight controlled trials were independently reviewed by two authors, with discrepancies addressed by a third.
Results: A total of 1491 AYA with T1D aged 12-39 (mean 18.5) years were represented in 17 publications. The most frequent intervention components included a transition coordinator (7), transition education (5), a multidisciplinary appointment (4), and a virtual transition program (4). Outcomes most frequently reported included HbA1c (12), satisfaction (10), psychological well-being (7), and continuity of care (7). Associations between interventions and outcomes are presented in Table 1.
Conclusions: There is a paucity of recent RCTs evaluating T1D transition interventions. While AYA with T1D reported satisfaction with a variety of interventions, programs including a transition coordinator and multidisciplinary appointment may also positively impact HbA1c, psychological well-being, and continuity of care.

Disclosure
E.L. Lundgrin: None. J.E. Blanchette: Consultant; Self; Dexcom, Inc., Tandem Diabetes Care. A. Mucci: None.
1373-P: Variables in Depression Screening Using PHQ-9 and PROMIS in Adolescents with T1DM
Authors: NADELLA SILPA , FRITZ SOBHA P. , MUIR ANDREW B. 
Published: June 2019

Background: Depression in teens with type 1 diabetes (T1DM) is associated with poor disease management. Multiple depression screening questionnaires are validated in teens with chronic disease; no ideal instrument has been identified.
Methods: Subjects aged 11 - 17 years with T1DM, completed the PROMIS and PHQ-9 on the same day (n=20), within 3 months (n=17), or within 6 months (n=11). PHQ-9 was completed by the subject and PROMIS was completed by the subject (PROMIS-Ch) and a parent (PROMIS-P). 1-way ANOVA determined statistical significance.
Results:
1. Subjects with no or mild risk of depression on PHQ-9 had a PROMIS-Ch or PROMIS-P score &gt;1.5 SD.
2. Clinical evaluation confirmed risk for depression in 5/6 subjects with moderate/severe risk on PHQ-9. PROMIS-Ch &gt;1.5 SD in 2/5 subjects and PROMIS-P score &gt;2 SD in 1/5 subjects.
3. Mean PHQ-9 score of 4 subjects with documented suicidal ideation (SI) was 18.4 (±6.7). The PROMIS-Ch was &gt;1.5 SD in 2 of 4; PROMIS-P was &gt;1.5 SD in 1 of 4.
Conclusions: Both surveys distinguished children at moderate/severe risk of depression from those with no/mild risk. Neither PROMIS survey distinguished between children who were at mild or no risk on PHQ-9. Those with SI had mean high risk PHQ-9 score, but did not have consistently high risk PROMIS scores. When screening for depression in adolescents, PHQ-9 had a higher sensitivity when compared to PROMIS.

Disclosure
S. Nadella: None. S.P. Fritz: None. A.B. Muir: None.
1374-P: Parent Preferences for Delaying Insulin Dependence in Children at Risk of Stage III Type 1 Diabetes (T1D)
Authors: HEDRICK JOSEPH , SUTPHIN JESSIE , DISANTOSTEFANO RACHAEL L. , GALLAHER KATHLEEN , MANSFIELD CAROL 
Published: June 2019

Purpose: Preference studies ascertain what is important to individuals when weighing benefits and risks of interventions. The purpose of this study was to investigate parents’ preferences for treatments to delay the onset of insulin dependence in children who will develop Stage III T1D.
Methods: A web-based discrete-choice experiment (DCE) survey measured the preferences of U.S. parents of children with T1D and without T1D. In a hypothetical scenario where their child (&lt;18 years) would become insulin dependent in 6 months or 2 years, respondents were offered a series of choices between hypothetical treatments that would delay insulin dependence or no treatment (monitoring only). Treatments were defined by 6 attributes with varying levels (years until insulin dependence; reductions in the risks of long-term complications, diabetic ketoacidosis (DKA), and serious infection; injection site reaction; and nausea). Random parameters logit analysis evaluated the relative importance of benefits and risks. Maximum acceptable risk (MAR) was calculated.
Results: Parents of children with T1D (n=600) and parents with children without T1D (n=901) from an online consumer panel completed the survey instrument. Most parents chose an active treatment (2% always chose monitoring only for all 8 choices). For parents without a T1D child, delaying insulin dependence and reducing the risk of long-term complications and serious infection were the most important treatment attributes, while parents with a T1D child valued these 3 attributes and reducing the risk of DKA as most important. MAR of serious infection ranged from 1%-7% for an additional 2 to 4-year delay in insulin dependence.
Conclusions: When told to assume their child would develop Stage III T1D, most parents considered hypothetical treatments to delay progression. The preferences expressed over the benefits and harms in this survey provide guidance on acceptable tradeoffs for future treatments to delay insulin dependence in T1D.

Disclosure
J. Hedrick: Employee; Self; Johnson & Johnson. Employee; Spouse/Partner; PTC Therapeutics. J. Sutphin: Other Relationship; Self; Multiple Companies. R.L. DiSantostefano: Employee; Self; Janssen Research & Development. K. Gallaher: Other Relationship; Self; Multiple companies. C. Mansfield: Other Relationship; Self; Multiple companies.

Funding
Janssen Research & Development, LLC
1390-P: Maternal Plasma Ceramides Predict Preeclampsia in Women with Type 1 Diabetes
Authors: KELLY CLARE B. , HAMMAD SAMAR M. , KLEIN RICHARD L. , LOPES-VIRELLA MARIA F. , LEYVA MISTI J. , YU JEREMY , JENKINS ALICIA J. , NANKERVIS ALISON J. , HANSSEN KRISTIAN F. , GARG SATISH K. , SCARDO JAMES A. , ASTON CHRISTOPHER E. , LYONS TIMOTHY 
Published: June 2019

The risk for preeclampsia (PE) is increased 4-fold in women with type 1 diabetes (T1D), in whom we previously demonstrated that elevated cholesterol-rich lipoproteins confer risk at the 1st trimester. Sphingolipids, including ceramides (Cer) and glycosphingolipids (hexosyl- (HexCer) and lactosyl-ceramides (LacCer)), are lipoprotein constituents that regulate cell signaling. We propose that these bio-active lipids could be modulators of PE risk.
In a prospective T1D pregnancy cohort (studied at 12, 22, 32 weeks’ gestation), we used liquid chromatography/electrospray ionization-tandem mass spectrometry to determine plasma levels of 12 species of Cer, HexCer, and LacCer in 23 women with T1DM who did vs. 24 who did not develop PE, and in 19 normotensive nondiabetic pregnant women. All were free of microalbuminuria and hypertension at enrolment; all visits preceded clinical PE onset.
Results: Plasma levels of C22-Cer (1st and 3rd study visits); C26:1-Cer (1st and 2nd visits); C26-Cer (1st visit); C18-Cer and C18:1-Cer (2nd visit) were significantly higher in women with T1DM who did vs. did not develop PE. C22-Cer and C26-Cer were significantly lower in T1DM vs. non-T1DM (1st visit). There were no overall PE- or diabetes-related differences in any HexCer- or LacCer species. Longitudinally, most Cer and HexCer species increased throughout pregnancy in all groups (except C14- and C18-Cer; and C14 and C26-HexCer). C16-LacCer increased, while C22:1-, C26-, and C26:1-LacCer decreased as pregnancy advanced, independent of PE status. Independent of LDL-C, total Cer increased throughout pregnancy in all groups.
Conclusions: Maternal Cer species may serve as early biomarkers for PE in women with T1DM. T1DM was associated with lower levels of two Cer species. Like cholesterol-rich lipoproteins, Cer, HexCer and some LacCer species increase as pregnancy advances in all groups, but other LacCer species decrease: the significance of these findings requires further study.

Disclosure
C.B. Kelly: None. S.M. Hammad: None. R.L. Klein: None. M.F. Lopes-Virella: None. M.J. Leyva: None. J. Yu: None. A.J. Jenkins: Advisory Panel; Self; Abbott, Australian Diabetes Society, Medtronic. Research Support; Self; Abbott, GlySens Incorporated, Medtronic, Mylan. Speaker's Bureau; Self; Eli Lilly and Company, Novo Nordisk Inc. A.J. Nankervis: None. K.F. Hanssen: None. S.K. Garg: Advisory Panel; Self; Eli Lilly and Company, Roche Pharma, Sanofi-Aventis, Zealand Pharma A/S. Research Support; Self; Eli Lilly and Company, WebMD. J.A. Scardo: None. C.E. Aston: None. T. Lyons: None.

Funding
JDRF; Novo Nordisk; National Institutes of Health
1394-P: The Role of the Unfolded Protein Response in High Glucose-Induced mESC Pluripotency and Impaired Differentiation
Authors: SUN WINNY , YANG PENGHUA , YE FEI , YANG PEIXIN 
Published: June 2019

Maternal diabetes is associated with various risks during pregnancy, including structural birth defects. Gene dysregulation and reduced progenitor cell formation and differentiation are two major mechanisms that are implicated in diabetic embryopathy. Our lab has previously shown that E14 mouse embryonic stem cells (mESCs) grown in high glucose conditions have delayed differentiation to both neurons and cardiomyocytes. However, treatment of 4-PBA (4-phenylbutyrate), a chemical chaperone used as an endoplasmic reticulum (ER) stress inhibitor, rescued this delay of differentiation to neurons. On the other hand, high glucose increased mESC pluripotency and activated the unfolded protein response (UPR) in undifferentiated conditions, specifically the protein kinase RNA-like endoplasmic reticulum kinase (PERK) pathway. To determine the role of the UPR in enhanced mESC pluripotency by high glucose, E14 mESCs grown in high glucose were treated with or without 4-PBA for 8 days. Untreated E14 mESCs grew in dome-shaped colonies with defined edges, while 4-PBA-treated cells grew in flat colonies with cells emerging out of the colonies, indicative of a more differentiated state. Microarray analysis showed that 4-PBA-treated cells had upregulated expression of primed state markers and downregulated expression of pluripotency markers, compared to untreated cells. Our results suggest that inhibition of the UPR through ER stress inhibition abolishes the stimulatory effect of high glucose on mESC pluripotency, leading to a shift from native state to a more differentiated ESC stage.

Disclosure
W. Sun: None. P. Yang: None. F. Ye: None. P. Yang: None.

Funding
National Institutes of Health
1397-P: A Pregnancy Lifestyle Intervention Improves Metabolic Profile of Women and Infants by Reducing Gestational Weight Gain (GWG): The GLOW Randomized Controlled Trial
Authors: FERRARA ASSIAMIRA , HEDDERSON MONIQUE M. , BROWN SUSAN D. , TSAI AI-LIN , FENG JUANRAN , ZHU YEYI , GALARCE MAREN N.R. , MARCOVINA SANTICA M. , QUESENBERRY CHARLES 
Published: June 2019

Among pregnant women with overweight or obesity, intensive interventions have reduced GWG but had only small effects on metabolic profile. In the Gestational weight gain and Optimal Wellness (GLOW) randomized controlled trial, we randomized pregnant women with overweight or obesity to a lifestyle intervention (n=199) or standard care (n=195) to evaluate the intervention’s efficacy in reducing GWG and improving metabolic biomarkers during pregnancy and in cord blood. Women in the intervention, vs. those in standard care, had significantly lower weekly rate of GWG from 10 to 32 weeks’ gestation (mean [SD], mean condition difference [95% CI]: 0.31 [0.18] vs. 0.42 [0.16], -0.11 [-0.15 to -0.08] kg/week) and lower total GWG (10.2 [5.6] vs. 12.4 [5.3], -2.2 [-3.3 to -1.1] kg). The intervention significantly reduced women’s fasting insulin, HOMA-IR and leptin from 10 to 32 weeks’ gestation and cord blood C-peptide, and yielded a borderline significant reduction of cord blood leptin (Table). The intervention’s effect on each biomarker was partially mediated by GWG, with the proportion of mediation effects ranging from 50 to 90% (all p-values &lt;.02). Reducing GWG via lifestyle intervention resulted in improved metabolic profile of women and their infants.

Disclosure
A. Ferrara: None. M.M. Hedderson: None. S.D. Brown: None. A. Tsai: None. J. Feng: None. Y. Zhu: None. M.N. Galarce: None. S.M. Marcovina: None. C. Quesenberry: None.

Funding
National Institutes of Health (NICHDR01HD073572, NIDDKP30DK092924)
14-LB: Somatostatin Receptor 2 Antagonism Enhances Plasma Glucagon Levels during Insulin-Induced Hypoglycemia in a Rodent Model of Type 2 Diabetes Mellitus
Authors: NEJAD-MANSOURI MEHRAN , ZAREE BAVANI PARINAZ , AIKEN JULIAN , DSOUZA NINOSCHKA C. , HOFFMAN EMILY G. , LIGGINS RICHARD , RIDDELL MICHAEL 
Published: June 2019

Somatostatin Receptor 2 antagonists (SSTR2a) increase glucagon counter-regulation to hypoglycemia in various rodent models of type-1 diabetes mellitus. Here we investigated the efficacy of SSTR2a in improving glucagon counter-regulation in a rat model of type-2 diabetes mellitus (T2DM). For this, male Sprague Dawley rats (n=18) were given a high fat diet for 3 weeks, followed by low-dose streptozotocin exposure (35 mg/kg, IP) to induce T2DM. Rats were then divided into SSTR2a treatment (PRL-2903, 10 mg/kg) or vehicle (n=9 for each) 1-hour before insulin-induced hypoglycemia (3 IU/kg NovoRapid). This process was repeated 1 week later in a cross-over design, with the data pooled over SSTR2a and vehicle treatments. A group of normal-chow-fed rats (n=3) served as nondiabetic controls. Mean blood glucose levels were higher at 20, 30, 40, and 50 minutes post insulin administration in the T2DM rats treated with PRL-2903, as compared to vehicle (p ≤ 0.05). The number of T2DM rats that developed biochemical hypoglycemia (blood glucose ≤ 3.5 mmol/L) tended to be less with PRL-2903 (5/18) vs. vehicle (9/18). Compared with vehicle treatment, PRL-2903 promoted higher plasma glucagon counter-regulation, as indicated by area under curve (AUC) analysis (p &lt; 0.05). Thus, SSTR2a treatment improves the attenuated glucagon response to hypoglycemia in T2DM rats.

Disclosure
M. Nejad-Mansouri: None. P. Zaree Bavani: None. J. Aiken: None. N.C. DSouza: None. E.G. Hoffman: None. R. Liggins: None. M. Riddell: Advisory Panel; Self; Xeris Pharmaceuticals, Inc. Research Support; Self; Dexcom, Inc. Speaker’s Bureau; Self; Insulet Corporation, Medtronic MiniMed, Inc. Stock/Shareholder; Self; Zucara Therapeutics Inc.

Funding
National Research Council Canada; Zucara Therapeutics
140-LB: NGM313, a Novel Activator of b-Klotho/FGFR1c, Improves Insulin Resistance and Reduces Hepatic Fat in Obese, Nondiabetic Subjects
Authors: DEPAOLI ALEX , PHUNG VAN , BASHIR MUSTAFA R. , MORROW LINDA , BEYSEN CARINE , YAN ANDREW , LING LEI , BAXTER BRYAN , LUSKEY KENNETH L. , OLEFSKY JERROLD M. 
Published: June 2019

Background: NGM313 is a humanized monoclonal antibody activator of β-klotho/FGFR1c that has been shown to reduce HOMA-IR in obese subjects. This study compared the effects of a single dose of NGM313 vs. daily pioglitazone (PIO) on insulin sensitivity, liver fat content (LFC) and lipids in insulin resistant, obese subjects with increased liver fat.
Methods: 25 subjects were randomized 2:1 to either a single dose of NGM313 240 mg SC (n=17) or PIO 45 mg PO QD (n=8) for 36 days. Whole-body insulin sensitivity was determined by a two-step hyperinsulinemic, euglycemic clamp and LFC by magnetic resonance imaging-proton density fat fraction (MRI-PDFF).
Results: (Table 1) A single dose of NGM313 significantly increased glucose disposal rate and was comparable to PIO. Suppression of endogenous glucose production was enhanced by both NGM313 and PIO. Significant reductions in LFC, HbA1c, serum triglycerides and LDL-C, and an increase in HDL-C, were observed with NGM313. NGM313 produced a greater reduction in LFC vs. PIO at day 23. The safety and tolerability profile was favorable for both drugs.
Conclusion: NGM313 is a potent insulin sensitizer, comparable to PIO. In addition, NGM313 is highly effective in reducing LFC in subjects with increased liver fat. As such, NGM313 has significant potential to be an effective treatment for nonalcoholic steatohepatitis and type 2 diabetes.

Disclosure
A. DePaoli: Employee; Self; NGM Biopharmaceuticals. V. Phung: Employee; Self; NGM Biopharmaceuticals. Stock/Shareholder; Self; NGM Biopharmaceuticals. M.R. Bashir: Consultant; Self; RadMD. Research Support; Self; Madrigal Pharmaceuticals, Metacrine Inc, NGM Biopharmaceuticals, Pinnacle Clinical Research, ProSciento, Siemens Corporation. L. Morrow: Employee; Spouse/Partner; Eli Lilly and Company. Employee; Self; ProSciento. C. Beysen: None. A. Yan: None. L. Ling: Employee; Self; NGM Biopharmaceuticals. Stock/Shareholder; Self; NGM Biopharmaceuticals. B. Baxter: Employee; Self; NGM Biopharmaceuticals. K.L. Luskey: Consultant; Self; NGM Biopharmaceuticals. J.M. Olefsky: None.
1403-P: Functional Data Analysis Reveals Differences in Temporal Glucose Profiles Associated with Large for Gestational Age: A Secondary Analysis of the CONCEPTT Study
Authors: SCOTT ELEANOR M. , MURPHY HELEN R. , FEIG DENICE , LAW GRAHAM 
Published: June 2019

Background: Continuous glucose monitoring (CGM) provides far greater detail about fetal exposure to maternal glucose across the 24 hour day, but recommended summary statistics give no dynamic information about the glucose profile across 24 hours.
Aim: To examine whether differences in temporal glucose control occur in women with type 1 diabetes who develop large for gestational age infants (LGA).
Research Design and Methods: CGM data was available from 200 pregnant women (100 CGM intervention; 100 controls) in the CONCEPTT study, at baseline, 24 and 34 weeks gestation. All women were being treated to tight glycemic targets (mean HbA1c 6.4% at 34 weeks gestation). Functional data analysis (FDA) was applied to determine differences in temporal glucose profiles. LGA was defined as birth weight ≥90th percentile adjusted for infant sex, gestational age, maternal BMI, ethnicity and parity.
Results: 122/200 women had a LGA infant (61%). FDA revealed that those women who gave birth to a LGA infant ran a significantly higher glucose (by 9-14mg/dL; 0.5-0.8 mmol/l) for 16.5 hours of the day compared to those women who did not have a LGA infant (see fig).
Conclusion: Women who go on to have LGA infants have significantly higher fetal exposure to glucose across the 24 hour day, despite being treated to tight glucose targets.

Disclosure
E.M. Scott: Advisory Panel; Self; Abbott. Speaker's Bureau; Self; Abbott, Eli Lilly and Company. H.R. Murphy: Advisory Panel; Self; Medtronic MiniMed, Inc. D. Feig: Advisory Panel; Self; Medtronic. Speaker's Bureau; Self; Medtronic. G. Law: None.

Funding
JDRF; Canadian Clinical Trials Network; National Institute for Health Research
1407-P: Laboratory Glycemic Markers vs. Continuous Glucose Monitoring (CGM) for Prediction of Neonatal Outcomes in Type 1 Diabetes Pregnancy—An Ancillary Study of the CONCEPTT Trial
Authors: MEEK CLAIRE L. , TUNDIDOR DIANA , MURPHY HELEN R. , YAMAMOTO JENNIFER M. , SCOTT ELEANOR M. , MA DONGDONG , HALPERIN JOSE , FEIG DENICE , CORCOY ROSA 
Published: June 2019

Type 1 diabetes (T1D) in pregnancy is associated with increased neonatal morbidity, which improves with optimal glycemic control.
Aim: To compare lab and CGM glucose summary measures as predictors of neonatal outcomes in T1D pregnancy.
Methods: 225 CONCEPTT participants had 6-day CGM and blood analysis of glycemic markers in 1st trimester, 24 and 34 weeks (Average glucose; % time in target 63-140 mg/dl, coefficient of variation (CV)); HbA1c; glycated CD59 (gCD59); 1,5-anhydroglucitol (1,5AG); glycated albumin). Outcomes: large for gestational age (LGA), neonatal hypoglycemia (NH) and neonatal intensive care unit (NICU) admission. Statistics: Unadjusted logistic regression.
Results: All glucose summary measures excluding CV predicted neonatal outcomes (Table). Glycemic control at all timepoints from 1st trimester was important for LGA, but emerged later for NH (24 and 34 weeks) and NICU (mainly 24 weeks). Both CGM time in target and average glucose and lab markers HbA1c, 1,5AG and gCD59 predicted all three outcomes studied. Time in target was the best CGM predictor. The best lab predictors were HbA1c, 1,5AG and gCD59. HbA1c was the strongest predictor of LGA and NH, but only predicted NICU admission late in pregnancy.
Conclusions: In women with T1D, both CGM and lab glucose summary measures can predict neonatal outcomes from 1st trimester.

Disclosure
C.L. Meek: None. D. Tundidor: None. H.R. Murphy: Advisory Panel; Self; Medtronic MiniMed, Inc. J.M. Yamamoto: None. E.M. Scott: Advisory Panel; Self; Abbott. Speaker's Bureau; Self; Abbott, Eli Lilly and Company. D. Ma: None. J. Halperin: Stock/Shareholder; Self; Mellitus, LLC. D. Feig: Advisory Panel; Self; Medtronic. Speaker's Bureau; Self; Medtronic. R. Corcoy: None.

Funding
JDRF; Canadian Clinical Trials Network; National Institute for Health Research; European Foundation for the Study of Diabetes/Sanofi; Diabetes UK (17/0005712 to C.L.M.); Asahi Kasei Pharma Corporation; GlycoMark, Inc.